2020
Erratum. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017;40:1010–1016
Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV. Erratum. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017;40:1010–1016. Diabetes Care 2020, 44: 298-298. PMID: 33158952, PMCID: PMC7783934, DOI: 10.2337/dc21-er01a.Peer-Reviewed Original ResearchAlcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi SM, Foster NC, Rash CJ, Van Name MA, Tamborlane WV, Cengiz E, Polsky S, Wagner J. Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange. Canadian Journal Of Diabetes 2020, 44: 501-506. PMID: 32792103, DOI: 10.1016/j.jcjd.2020.06.005.Peer-Reviewed Original ResearchConceptsBody mass indexSevere hypoglycemiaFormer drinkersLower oddsAlcohol consumptionNonbinge drinkersType 1Current binge drinkersPresence of neuropathyDiabetes-related distressDiabetes-related outcomesType 1 diabetesCross-sectional studyYears of ageNon-Hispanic whitesDiabetic ketoacidosisRecent severe hypoglycemiaMedical chartsClinical outcomesMass indexProspective studyDiabetes distressBlood glucoseBinge drinkersDrinking status
2019
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics 2019, 21: 66-72. PMID: 30657336, PMCID: PMC7061293, DOI: 10.1089/dia.2018.0384.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringT1D Exchange RegistryRegistry participantsDiabetes managementHigher mean HbA1cType 1 diabetesType 1 diabetes managementMinority of adultsProfile of adultsHbA1c goalDiabetic ketoacidosisMean HbA1cSevere hypoglycemiaClinical outcomesT1D ExchangeT1D managementAge 30Longitudinal changesADA goalsAge 28Age 15Glucose monitoringYoung adultsCGM usersRacial differences
2017
Continuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial
Galderisi A, Facchinetti A, Steil GM, Ortiz-Rubio P, Cavallin F, Tamborlane WV, Baraldi E, Cobelli C, Trevisanuto D. Continuous Glucose Monitoring in Very Preterm Infants: A Randomized Controlled Trial. Pediatrics 2017, 140: e20171162. PMID: 28916591, DOI: 10.1542/peds.2017-1162.Peer-Reviewed Original ResearchConceptsVery preterm infantsGlucose infusion rateContinuous glucose monitoringPreterm infantsCGM groupPercentage of timeEuglycemic rangeSevere hyperglycemiaSevere hypoglycemiaGlycemic variabilityGlucose monitoringCare blood glucose monitoringUse of CGMPoor neurologic outcomeImpaired glucose controlBlood glucose monitoringBlood glucose determinationNeurologic outcomeSecondary outcomesInsulin titrationPrimary outcomeWeeks' gestationControlled TrialsGlucose controlBirth weightPostprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry
Peters A, Van Name MA, Thorsted B, Piltoft JS, Tamborlane WV. Postprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry. Endocrine Practice 2017, 23: 1201-1209. PMID: 28704103, DOI: 10.4158/ep171813.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolCross-Sectional StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Dosage CalculationsFemaleHumansHypoglycemiaInfantInsulinInsulin Infusion SystemsMaleMiddle AgedPostprandial PeriodRegistriesYoung AdultConceptsRapid-acting insulin analoguesLarger insulin doseT1D Exchange RegistryType 1 diabetesCross-sectional studyDiabetic ketoacidosisInsulin doseGreater prevalenceCurrent rapid-acting insulin analoguesInsulin analoguesSelf-monitoring blood glucosePercent of patientsCharacteristics of patientsPoor glycemic controlExclusion of patientsBody mass indexContinuous glucose monitoringPostprandial dosingGlycemic controlSevere hypoglycemiaBolus insulinMass indexEnrollment questionnaireBlood glucoseGlucose levelsThe Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV, Group T. The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017, 40: dc162723. PMID: 28550194, PMCID: PMC5521975, DOI: 10.2337/dc16-2723.Peer-Reviewed Original ResearchConceptsSevere hypoglycemiaTreatment groupsMean HbADiabetes therapyDCCT/EDIC cohortDCCT/EDIC studyIntensive diabetes therapyIntensive treatment groupSevere hypoglycemia ratesConventional treatment groupDuration of diabetesConventional diabetes therapyType 1 diabetesComplications (DCCT/EDIC) cohortEDIC studySimilar HbAComplications TrialHypoglycemia ratesLower HbADiabetes controlDCCT studyRisk factorsRelative riskHypoglycemiaLower risk
2016
Characteristics of youth with type 1 diabetes (T1D) with and without a parent with T1D in the T1D exchange clinic registry
Fox LA, Mubasher M, Wolfsdorf JI, Buckingham BA, Peters AL, Tamborlane WV, Schatz DA, Maahs DM, Miller KM, Beck RW, Network F. Characteristics of youth with type 1 diabetes (T1D) with and without a parent with T1D in the T1D exchange clinic registry. Journal Of Diabetes 2016, 8: 834-838. PMID: 26663683, DOI: 10.1111/1753-0407.12363.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetic ketoacidosisT1D Exchange Clinic RegistryInsulin pump therapyT1D Exchange RegistryContinuous glucose monitoringAcute complicationsGlycemic controlSevere hypoglycemiaClinic registryPump therapyPresent studyDiabetes managementT1D.T1DStudy participantsGlucose monitoringLinear mixed modelsDiabetesRegistryCharacteristics of youthChildrenAdolescentsMixed modelsStatistical comparisonGlucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2015
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2015, 39: 264-270. PMID: 26681725, PMCID: PMC4722945, DOI: 10.2337/dc15-1498.Peer-Reviewed Original ResearchConceptsInsulin-induced hypoglycemiaType 1 diabetesIntramuscular glucagonIntranasal glucagonSevere hypoglycemiaPlasma glucoseCrossover noninferiority trialTreatment of hypoglycemiaLoss of consciousnessReal-world managementDosing visitsGlucagon responseIntravenous insulinNoninferiority studyGlucagon administrationClinical centersFacial discomfortNoninferiority trialHospital settingGlucagon preparationHypoglycemiaTherapeutic insulinGlucagonType 1Mean timeCombining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas
Ang KH, Tamborlane WV, Weinzimer SA. Combining glucose monitoring and insulin delivery into a single device: current progress and ongoing challenges of the artificial pancreas. Expert Opinion On Drug Delivery 2015, 12: 1579-1582. PMID: 26389567, PMCID: PMC4837694, DOI: 10.1517/17425247.2015.1074174.Peer-Reviewed Original ResearchConceptsBurden of careGlucose monitoringInsulin deliveryMultiple hormone systemsOverall glucose levelsType 1 diabetesContinuous glucose monitoringGlycemic targetsSevere hypoglycemiaDiabetes controlInsulin delivery systemsInpatient settingGlucose levelsPharmacokinetic profileOutpatient environmentInsulin analoguesPump suspensionInsulin pumpHypoglycemiaPsychosocial tollHormone systemTarget rangeArtificial pancreasPreliminary findingsCareObesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States
DuBose SN, Hermann JM, Tamborlane WV, Beck RW, Dost A, DiMeglio LA, Schwab KO, Holl RW, Hofer SE, Maahs DM, Willi S, Lipman T, Calvano T, Kucheruk O, Minnock P, Nguyen C, Klingensmith G, Banion C, Barker J, Cain C, Chase P, Hoops S, Kelsy M, Klingensmith G, Maahs D, Mowry C, Nadeau K, Raymond J, Rewers M, Rewers A, Slover R, Steck A, Wadwa P, Walravens P, Zeitler P, Haro H, Manseau K, Weinstock R, Izquierdo R, Sheikh U, Conboy P, Bulger J, Bzdick S, Goland R, Gandica R, Weiner L, Cook S, Greenberg E, Kohm K, Pollack S, Lee J, Gregg B, Tan M, Burgh K, Eason A, Garg S, Michels A, Myers L, DiMeglio L, Hannon T, Orr D, Cruz C, Woerner S, Wolfsdorf J, Quinn M, Tawa O, Ahmann A, Castle J, Joarder F, Bogan C, Cady N, Cox J, Pitts A, Fitch R, White B, Wollam B, Bode B, Lindmark K, Hosey R, Bethin K, Quattrin T, Ecker M, Wood J, Chao L, Cheung C, Fisher L, Jeandron D, Kaufman F, Kim M, Miyazaki B, Monzavi R, Patel P, Pitukcheewanont P, Sandstrom A, Cohen M, Ichihara B, Lipton M, Cemeroglu A, Appiagyei-Dankah Y, Daniel M, Postellon D, Racine M, Wood M, Kleis L, Hirsch I, DeSantis A, Dugdale D, Failor R, Gilliam L, Greenbaum C, Janci M, Odegard P, Trence D, Wisse B, Batts E, Dove A, Hefty D, Khakpour D, Klein J, Kuhns K, McCulloch-Olson M, Peterson C, Ramey M, St. Marie M, Thomson P, Webber C, Liljenquist D, Sulik M, Vance C, Coughenour T, Brown C, Halford J, Prudent A, Rigby S, Robison B, Starkman H, Berry T, Cerame B, Chin D, Ebner-Lyon L, Guevarra F, Sabanosh K, Silverman L, Wagner C, Fox M, Buckingham B, Shah A, Caswell K, Harris B, Bergenstal R, Criego A, Damberg G, Matfin G, Powers M, Tridgell D, Burt C, Olson B, Thomas L, Mehta S, Katz M, Laffel L, Hathway J, Phillips R, Cengiz E, Tamborlane W, Cappiello D, Steffen A, Zgorski M, Peters A, Ruelas V, Benjamin R, Adkins D, Cuffee J, Spruill A, Bergenstal R, Criego A, Damberg G, Matfin G, Powers M, Tridgell D, Burt C, Olson B, Thomas J, Aleppo-Kacmarek G, Derby T, Massaro E, Webb K, Solorzano C, DeBoer M, Madison H, McGill J, Buechler L, Clifton M, Hurst S, Kissel S, Recklein C, Tsalikian E, Tansey M, Cabbage J, Coffey J, Salamati S, Clements M, Raman S, Turpin A, Bedard J, Cohoon C, Elrod A, Fridlington A, Hester L, Kruger D, Schatz D, Clare-Salzler M, Cusi K, Digman C, Fudge B, Haller M, Meehan C, Rohrs H, Silverstein J, Wagh S, Cintron M, Sheehan E, Thomas J, Daniels M, Clark S, Flannery T, Forghani N, Naidu A, Reh C, Scoggin P, Trinh L, Ayala N, Quintana R, Speer H, Zipf W, Seiple D, Kittelsrud J, Gupta A, Peterson V, Stoker A, Gottschalk M, Hashiguchi M, Smith K, Rodriguez H, Bobik C, Henson D, Simmons J, Potter A, Black M, Brendle F, Gubitosi-Klug R, Kaminski B, Bergant S, Campbell W, Tasi C, Copeland K, Beck J, Less J, Schanuel J, Tolbert J, Adi S, Gerard-Gonzalez A, Gitelman S, Chettout N, Torok C, Pihoker C, Yi-Frazier J, Kearns S, Libman I, Bills V, Diaz A, Duke J, Nathan B, Moran A, Bellin M, Beasley S, Kogler A, Leschyshyn J, Schmid K, Street A, Nelson B, Frost C, Reifeis E, Haymond M, Bacha F, Caldas-Vasquez M, Klinepeter S, Redondo M, Berlanga R, Falk T, Garnes E, Gonzalez J, Martinez C, Pontifes M, Yulatic R, Arnold K, Evans T, Sellers S, Raman V, Foster C, Murray M, Raman V, Brown T, Slater H, Wheeler K, Harlan D, Lee M, Lock J, Hartigan C, Hubacz L, Buse J, Calikoglu A, Largay J, Young L, Brown H, Duncan V, Duclos M, Tricome J, Brandenburg V, Blehm J, Hallanger-Johnson J, Hanson D, Miller C, Weiss J, Hoffman R, Chaudhari M, Repaske D, Gilson E, Haines J, Rudolph J, McClave C, Biersdorf D, Tello A, Blehm J, Amundson D, Ward R, Rickels M, Dalton-Bakes C, Markman E, Peleckis A, Rosenfeld N, Dolan L, Corathers S, Kichler J, Baugh H, Standiford D, Hassing J, Jones J, Willis S, Willis S, Wysham C, Davis L, Blackman S, Abel K, Clark L, Jonas A, Kagan E, Sosenko J, Blashke C, Matheson D, Edelen R, Repas T, Baldwin D, Borgwardt T, Conroy C, DeGrote K, Marchiando R, Wasson M, Fox L, Mauras N, Damaso L, Englert K, Hamaty M, Kennedy L, Schweiger M, Konstantinopoulos P, Mawhorter C, Orasko A, Rose D, Deeb L, Rohrbacher K, Schroeder L, Roark A, Ali O, Kramer J, Whitson-Jones D, Potter A, Black M, Brendle F, Gassner H, Kollipara S, Bills V, Duke J, Harwood K, Prasad V, Brault J. Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. The Journal Of Pediatrics 2015, 167: 627-632.e4. PMID: 26164381, DOI: 10.1016/j.jpeds.2015.05.046.Peer-Reviewed Original ResearchConceptsBody mass index z-scoreProspective Follow-upType 1 diabetesSevere hypoglycemiaT1D ExchangeFollow-upGreater body mass index z-scoreOptimal glycemic controlIndex z-scoreMedian BMI valuesNational reference valuesGlycemic controlClinical registryGreater hemoglobinChildren 2BMI valuesBMI referencesAge groupsRegistryZ-scoreExcessive weightHypoglycemiaObesity problemObesityDiabetesCurrent State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care 2015, 38: 971-978. PMID: 25998289, DOI: 10.2337/dc15-0078.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesT1D Exchange Clinic RegistryContinuous glucose monitoringDiabetic ketoacidosisSevere hypoglycemiaClinic registryMetabolic controlOutcome of treatmentOptimal metabolic controlRegistry findingsAdvanced diabetes technologiesAverage HbA1cMean hemoglobinYounger patientsCommon complicationCurrent treatmentNew therapiesAge 30HbA1cType 1DiabetesGlucose monitoringDiabetes technologyAgeRacial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes
Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH. Racial-Ethnic Disparities in Management and Outcomes Among Children With Type 1 Diabetes. Pediatrics 2015, 135: 424-434. PMID: 25687140, PMCID: PMC4533245, DOI: 10.1542/peds.2014-1774.Peer-Reviewed Original ResearchConceptsHispanic participantsEthnic disparitiesSocioeconomic statusDiabetic ketoacidosisHemoglobin A1cT1D Exchange Clinic RegistryMean hemoglobin A1cLarge pediatric cohortOptimal glycemic controlSevere hypoglycemic eventsBlack participantsType 1 diabetesMore Black participantsNon-Hispanic blacksGlycemic controlSevere hypoglycemiaClinic registryClinical outcomesPediatric cohortHypoglycemic eventsDiabetes outcomesTreatment outcomesTherapeutic modalitiesDiabetes managementDiabetes treatment
2013
A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience
Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW, Cengiz E, Laffel LM, Miller KM, Haller MJ, Network F. A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatric Diabetes 2013, 15: 110-117. PMID: 23957219, PMCID: PMC4164957, DOI: 10.1111/pedi.12067.Peer-Reviewed Original ResearchConceptsGlycemic controlPoor controlMean total daily insulin doseControl groupTotal daily insulin doseExcellent control groupExcellent glycemic controlPediatric type 1 diabetesDaily insulin doseType 1 diabetesPoor control groupMeal-time insulinLong-term riskBlood glucose monitoringDiabetes durationBolus insulinInsulin doseSevere hypoglycemiaRegistry experienceBlood glucoseSelf-management techniquesCare providersParticipants 6Time insulinDiabetes managementSevere hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry
Cengiz E, Xing D, Wong JC, Wolfsdorf JI, Haymond MW, Rewers A, Shanmugham S, Tamborlane WV, Willi SM, Seiple DL, Miller KM, DuBose SN, Beck RW, Network F. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatric Diabetes 2013, 14: 447-454. PMID: 23469984, PMCID: PMC4100244, DOI: 10.1111/pedi.12030.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryDiabetic ketoacidosisSevere hypoglycemiaClinic registryFrequency of SHOccurrence of SHRisk of DKASerious acute complicationsPoor glycemic controlHigh-risk groupAssociation of baselineNew treatment paradigmSeparate logistic regression modelsNon-white raceLower household incomeLogistic regression modelsYoung adult cohortDKA frequencyAcute complicationsClinical factorsGlycemic controlHigher HbA1cT1D ExchangeTreatment paradigm
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter Randomized TrialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetesA Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years
Mauras N, Beck R, Xing D, Ruedy K, Buckingham B, Tansey M, White NH, Weinzimer SA, Tamborlane W, Kollman C, . A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years. Diabetes Care 2012, 35: 204-210. PMID: 22210571, PMCID: PMC3263860, DOI: 10.2337/dc11-1746.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringGlycemic controlPrimary outcomeParental satisfactionReal-time continuous glucose monitoringGlucose monitoringSevere hypoglycemia ratesDays/weekGlucose dataUsual careHypoglycemia ratesSevere hypoglycemiaCGM groupClinical trialsChildren Aged 4Control groupDiabetesHypoglycemiaDay managementAged 4WeeksParental fearYoung childrenChildren
2010
Continuous Glucose Monitoring in Youth with Type 1 Diabetes: 12-Month Follow-Up of the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial
Chase HP, Beck RW, Xing D, Tamborlane WV, Coffey J, Fox LA, Ives B, Keady J, Kollman C, Laffel L, Ruedy KJ. Continuous Glucose Monitoring in Youth with Type 1 Diabetes: 12-Month Follow-Up of the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Technology & Therapeutics 2010, 12: 507-515. PMID: 20597824, DOI: 10.1089/dia.2010.0021.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringUse of CGMDays/weekCGM useMonth 12Glucose monitoringSevere hypoglycemic eventsType 1 diabetesJuvenile Diabetes Research Foundation Continuous Glucose MonitoringBaseline hemoglobinGlycemic controlSevere hypoglycemiaPediatric populationHypoglycemic eventsSubjects 8Extension studyType 1MonthsT1DGreater improvementTrialsWeeksGreater satisfactionSubjectsSatisfaction ScaleEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal Of Medicine 2010, 363: 311-320. PMID: 20587585, DOI: 10.1056/nejmoa1002853.Peer-Reviewed Original ResearchConceptsInjection therapy groupPump-therapy groupSensor-augmented pump therapyGlycated hemoglobin levelsHemoglobin levelsType 1 diabetesPump therapyBaseline glycated hemoglobin levelMultiple daily insulin injectionsType 1 diabetes mellitusGlycated haemoglobin targetPrimary end pointProportion of patientsDaily insulin injectionsSignificant weight gainRecombinant insulin analogueHemoglobin targetsInjection therapyDiabetes mellitusSevere hypoglycemiaInsulin injectionsClinical teamInsulin analoguesEnd pointTherapySTAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomes